Compare · EVGN vs UAN
EVGN vs UAN
Side-by-side comparison of Evogene Ltd (EVGN) and CVR Partners LP (UAN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EVGN and UAN operate in Agricultural Chemicals (Industrials), so they compete in similar markets.
- UAN is the larger of the two at $1.29B, about 206.3x EVGN ($6.2M).
- Over the past year, EVGN is down 45.5% and UAN is up 46.5% - UAN leads by 91.9 points.
- EVGN has hit the wire 6 times in the past 4 weeks while UAN has been quiet.
- EVGN has more recent analyst coverage (4 ratings vs 0 for UAN).
- Company
- Evogene Ltd
- CVR Partners LP
- Price
- $0.60+0.42%
- $121.27+0.41%
- Market cap
- $6.2M
- $1.29B
- 1M return
- -23.09%
- -9.76%
- 1Y return
- -45.45%
- +46.48%
- Industry
- Agricultural Chemicals
- Agricultural Chemicals
- Exchange
- NASDAQ
- NYSE
- IPO
- 2011
- News (4w)
- 6
- 0
- Recent ratings
- 4
- 0
Evogene Ltd
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd., a subsidiary of Tikun Olam-Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
CVR Partners LP
CVR Partners, LP, together with its subsidiaries, produces and distributes nitrogen fertilizer products in the United States. The company offers ammonia products for agricultural and industrial customers; and urea and ammonium nitrate products to agricultural customers, as well as retailers and distributors. CVR GP, LLC serves as the general partner of the company. CVR Partners, LP was founded in 2007 and is based in Sugar Land, Texas.
Latest EVGN
- Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica
- SEC Form 424B3 filed by Evogene Ltd
- SEC Form 6-K filed by Evogene Ltd
- Evogene Reports First Quarter 2026 Financial Results
- SEC Form 6-K filed by Evogene Ltd
- Evogene to Present at the 24th Schrödinger European User Group Meeting
- Evogene Schedules First Quarter 2026 Financial Results Release
- SEC Form EFFECT filed by Evogene Ltd
- SEC Form 3 filed by new insider Ravzin Polina
- SEC Form EFFECT filed by Evogene Ltd
Latest UAN
- SEC Form 10-Q filed by CVR Partners LP
- CVR Partners LP filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- CVR Partners Reports First Quarter 2026 Results
- CVR Partners to Release First Quarter 2026 Earnings Results
- SEC Form 3 filed by new insider Turbidy Trevor
- CVR Partners LP filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- CVR Partners LP filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- CVR Partners Files Form 10-K Annual Report For Fiscal Year Ended December 31, 2025
- SEC Form 10-K filed by CVR Partners LP
- CVR Partners LP filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits